Restore: 'for up to $100M'; 'Abbott agreed to acquire Exact Sciences for $105/share (~$21B equity, ~$23B enterprise value)' (per MDxHealth and Abbott sources on the record).
Key facts
AnnouncedJul 29, 2019
ClosedNov 08, 2019
Deal value$2.8B
Deal typeAcquisition/Merger
Therapeutic areaOncology
IndicationsBreast cancer recurrence risk assessment, Prostate cancer genomic profiling, Colon cancer recurrence risk assessment
Key assetsOncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score, Oncotype DX Colon Recurrence Score, Genomic Health CLIA-certified laboratory (Redwood City), International commercial infrastructure (90+ countries), TAILORx clinical trial data supporting Oncotype DX
MechanismMultigene RT-PCR expression assay, Genomic profiling for treatment decisions